​

Repligen (RGEN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGEN Stock Forecast

Repligen (RGEN) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $220.00, with a high of $220.00 and a low of $220.00. This represents a 69.23% increase from the last price of $130.00.

$125 $144 $163 $182 $201 $220 High: $220 Avg: $220 Low: $220 Last Closed Price: $130

RGEN Stock Rating

Repligen stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 1 Strong Buy (5.00%), 16 Buy (80.00%), 3 Hold (15.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 3 16 1 Strong Sell Sell Hold Buy Strong Buy

RGEN Price Target Upside V Benchmarks

TypeNameUpside
StockRepligen69.23%
SectorHealthcare Stocks 35.25%
IndustryMedical Instruments & Supplies Stocks34.02%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$193.40
Last Closing Price$130.00$130.00$130.00
Upside/Downside--48.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25496--19
Mar, 253106--19
Feb, 25396--18
Jan, 25396--18
Dec, 24395--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Paul KnightKeyBanc$220.00$148.5948.06%69.23%
Jul 31, 2024Rachel VatnsdalJ.P. Morgan$200.00$167.3519.51%53.85%
Jul 31, 2024Elizabeth GarciaUBS$185.00$167.3510.55%42.31%
Jun 26, 2024Justin BowersDeutsche Bank$155.00$127.0022.05%19.23%
Jun 21, 2024Daniel AriasStifel Nicolaus$207.00$123.1668.07%59.23%
Jan 06, 2023Leerink Partners$200.00$153.3230.45%53.85%
Dec 14, 2022Deutsche Bank$180.00$177.991.13%38.46%
Dec 07, 2022RBC Capital$190.00$169.1312.34%46.15%
Apr 28, 2022Leerink Partners$220.00$157.5139.67%69.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2024KeyBancOverweightOverweighthold
Sep 26, 2024UBSUnderperformUnderperformhold
Aug 27, 2024Wells FargoOverweightinitialise
Jul 31, 2024UBSBuyBuyhold
Jun 26, 2024BMO CapitalOutperformupgrade
Jun 26, 2024Deutsche BankHoldBuyupgrade
Jun 18, 2024GuggenheimNeutralinitialise
Feb 21, 2024William BlairOutperformOutperformhold
Oct 31, 2023William BlairOutperformOutperformhold
Jul 06, 2023Piper SandlerUnderweightdowngrade

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.14$2.33$3.35$0.64$-0.46----
Avg Forecast$1.44$2.90$3.18$1.73$1.54$1.74$2.22$2.70$3.47
High Forecast$1.47$2.96$3.24$1.77$1.58$1.83$2.45$3.06$3.54
Low Forecast$1.40$2.82$3.12$1.70$1.51$1.58$1.78$2.26$3.38
Surprise %-20.83%-19.66%5.35%-63.01%-129.87%----

Revenue Forecast

$300M $460M $620M $780M $940M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$366.26M$670.53M$801.54M$632.36M$634.44M----
Avg Forecast$351.59M$664.36M$799.57M$638.45M$634.11M$695.52M$795.79M$906.21M$1.06B
High Forecast$357.01M$674.59M$810.89M$640.73M$636.51M$700.21M$798.66M$924.49M$1.08B
Low Forecast$344.55M$651.05M$787.36M$634.53M$632.52M$683.80M$792.92M$887.93M$1.04B
Surprise %4.17%0.93%0.25%-0.95%0.05%----

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$59.93M$128.29M$185.96M$35.60M$-25.51M----
Avg Forecast$36.77M$80.76M$123.55M$41.58M$87.14M$96.13M$119.29M$149.89M$195.63M
High Forecast$44.12M$96.91M$148.26M$49.89M$89.12M$102.99M$138.23M$172.50M$199.72M
Low Forecast$29.41M$64.61M$98.84M$33.26M$85.17M$89.26M$100.34M$127.28M$190.28M
Surprise %62.99%58.85%50.52%-14.39%-129.28%----

RGEN Forecast FAQ

Is Repligen stock a buy?

Repligen stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 16 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Repligen is a favorable investment for most analysts.

What is Repligen's price target?

Repligen's price target, set by 20 Wall Street analysts, averages $220 over the next 12 months. The price target range spans from $220 at the low end to $220 at the high end, suggesting a potential 69.23% change from the previous closing price of $130.

How does Repligen stock forecast compare to its benchmarks?

Repligen's stock forecast shows a 69.23% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the medical instruments & supplies stocks industry (34.02%).

What is the breakdown of analyst ratings for Repligen over the past three months?

  • April 2025: 21.05% Strong Buy, 47.37% Buy, 31.58% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 15.79% Strong Buy, 52.63% Buy, 31.58% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Repligen’s EPS forecast?

Repligen's average annual EPS forecast for its fiscal year ending in December 2025 is $1.74, marking a -478.26% decrease from the reported $-0.46 in 2024. Estimates for the following years are $2.22 in 2026, $2.7 in 2027, and $3.47 in 2028.

What is Repligen’s revenue forecast?

Repligen's average annual revenue forecast for its fiscal year ending in December 2025 is $695.52M, reflecting a 9.63% increase from the reported $634.44M in 2024. The forecast for 2026 is $795.79M, followed by $906.21M for 2027, and $1.06B for 2028.

What is Repligen’s net income forecast?

Repligen's net income forecast for the fiscal year ending in December 2025 stands at $96.13M, representing a -476.76% decrease from the reported $-25.514M in 2024. Projections indicate $119.29M in 2026, $149.89M in 2027, and $195.63M in 2028.